Myelodysplastic syndrome with mutated TP53 is considered together with MDS/AML and AML with mutated TP53 in the ICC as myeloid neoplasms with mutated TP53 because of their overall similar aggressive behaviour that warrants a more unified treatment strategy across the blast spectrum. This evidence concerns the gene TP53 and acute myeloid leukemia.